{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-023035","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.993612+00:00","generated_at":"2026-06-02T00:10:59.360442+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rockwell Medical Q1 record sales $22.7M (+15% YoY); raises 2024 guidance across all metrics","bullets":["Q1 net sales $22.7M (record), up 15% YoY; ex-deferred revenue, up 25%. Gross profit $3.1M (+18% YoY).","Net loss improved to $1.7M from $1.8M YoY; adjusted EBITDA ($0.5M) vs ($1.0M).","Raised FY2024 guidance: net sales $90-94M (prev $84-88M); gross profit $13-15M; adjusted EBITDA $0.5-1.0M.","Amended Innovatus loan: rate reduced, maturity extended to Jan 2029; interest-only through Sep 2026.","New distribution deals with BioNuclear and AMI expected ~$1M annual revenue; new supply agreement with large Mountain West health system."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-023035","json":"https://secwatch.observer/filing/0001628280-24-023035.json","markdown":"https://secwatch.observer/filing/0001628280-24-023035.md","text":"https://secwatch.observer/filing/0001628280-24-023035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000162828024023035/0001628280-24-023035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000162828024023035/rmti-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:10:59.360442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa82a51b06187ae9b5fab2c005405c72c2834edb","claim":"ROCKWELL MEDICAL, INC. reported three months ended March 31, 2024 results: revenue $22.7 million, net income Net loss of $1.7 million, EPS $(0.06). Guidance raised.","evidence_excerpt":"by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Rockwell Medical Announces First Quarter 2024 Results, Raises 2024 Guidance • Reports record net sales of $22.7 million for the first quarter of 2024, an increase of 25% over net product sales and a 15% increase over net sales for the same period in 2023. • Reports record gross profit of $3.1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828024023035/0001628280-24-023035-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$22.7 million"},{"label":"Net income","value":"Net loss of $1.7 million"},{"label":"EPS","value":"$(0.06)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}